FHH1 accounts for ~65% of all FHH cases with >150 different loss-of-function CASR mutations reported, and a recent population-based study indicating a genetic prevalence of ~75/100,000. The gene discussed is CASR; the disease is familial hypocalciuric hypercalcemia.